Monoclonal antibodyFDA-approvedSecond-line
Inotuzumab ozogamicin
How it works
Binds to CD22 on cancer cells, marking them for immune destruction and blocking their growth signals.
Cancer types
Leukemia— CD22-positive
Efficacy
In clinical trials, around 50% of patients with relapsed or refractory ALL achieved a complete remission, with a median overall survival of approximately 8 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Inotuzumab Ozogamicin and Chemotherapy for High-Risk Leukemia Patients | Leukemia | phase-3 | — | Source → |
| New Treatment for Young Adults with B Acute Lymphoblastic Leukemia | Leukemia | phase-3 | — | Source → |
| Testing a New Combination Therapy for Adults with B-Cell Leukemia or Lymphoma | Leukemia | phase-2 | — | Source → |
| Testing Inotuzumab Ozogamicin in Children with Relapsed Acute Lymphoblastic Leukemia | Leukemia | phase-2 | — | Source → |
| Testing Combination Therapy for CD22-Positive B-Lineage Acute Lymphoblastic Leukemia | Leukemia | phase-2 | — | Source → |
| Inotuzumab Ozogamicin's Role in Treating Acute Lymphoblastic Leukemia | Leukemia | review | — | Source → |
| Inotuzumab Ozogamicin Efficacy in Relapsed/Refractory Acute Lymphoblastic Leukemia | Leukemia | observational | Complete remission or remission with incomplete recovery was achieved in 74% of patients. | Source → |
| Immunotherapy Response Varies in B-ALL Patients | Leukemia | observational | — | Source → |
| Researchers Identify Key Factor in Leukemia Resistance to Inotuzumab Ozogamicin | Leukemia | lab-study | — | Source → |
| New Treatment Option for Relapsed Leukemia Patients | Leukemia | observational | All four patients achieved complete remission after the first InO cycle. | Source → |
| Combining Immunotherapy with Chemotherapy for Adult B-Cell Leukemia | Leukemia | phase-2 | — | Source → |
| Bridging Therapy and CAR-T Cell Expansion in Leukemia | Leukemia | lab-study | Achieving or maintaining low tumor burden significantly improved event-free survival in 12 months (81.8% and 100% respectively) vs 25% for patients who maintained high tumor burden. | Source → |
| Single-Agent Inotuzumab Ozogamicin Therapy for Relapsed Leukemia in a Child with Down Syndrome | Leukemia | observational | — | Source → |
| Combining Olverembatinib and Inotuzumab Ozogamicin for Leukemia Treatment | Leukemia | preclinical | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.